Cargando…
Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience
During past years, the increasing knowledge of molecular mechanisms of inflammatory bowel disease (IBD) have led to the development of several targeted biological therapies. This great expansion of available medical options has prompted the need for comparative data between drugs. For years, given t...
Autores principales: | Macaluso, Fabio Salvatore, Maida, Marcello, Grova, Mauro, Crispino, Federica, Teresi, Giulia, Orlando, Adele, Orlando, Ambrogio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111554/ https://www.ncbi.nlm.nih.gov/pubmed/33995582 http://dx.doi.org/10.1177/17562848211010668 |
Ejemplares similares
-
Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?
por: Macaluso, Fabio Salvatore, et al.
Publicado: (2021) -
COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data
por: Macaluso, Fabio Salvatore, et al.
Publicado: (2020) -
Reply to Comment on: “Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease”
por: Macaluso, Fabio Salvatore, et al.
Publicado: (2023) -
Ustekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseases
por: Viola, Anna, et al.
Publicado: (2021) -
Exit strategies in inflammatory bowel disease: Looking beyond anti-tumor necrosis factors
por: Crispino, Federica, et al.
Publicado: (2023)